- Home
- AVXL vs REPL Comparison
AVXL vs REPL Comparison
Compare AVXL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- REPL
- Stock Information
- Founded
- AVXL 2004
- REPL 2015
- Country
- AVXL United States
- REPL United States
- Employees
- AVXL N/A
- REPL N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- REPL Health Care
- Exchange
- AVXL Nasdaq
- REPL Nasdaq
- Market Cap
- AVXL 710.3M
- REPL 753.9M
- IPO Year
- AVXL N/A
- REPL 2018
- Fundamental
- Price
- AVXL $9.09
- REPL $9.27
- Analyst Decision
- AVXL Strong Buy
- REPL Strong Buy
- Analyst Count
- AVXL 2
- REPL 7
- Target Price
- AVXL $44.00
- REPL $20.83
- AVG Volume (30 Days)
- AVXL 768.8K
- REPL 1.3M
- Earning Date
- AVXL 08-05-2025
- REPL 08-07-2025
- Dividend Yield
- AVXL N/A
- REPL N/A
- EPS Growth
- AVXL N/A
- REPL N/A
- EPS
- AVXL N/A
- REPL N/A
- Revenue
- AVXL N/A
- REPL N/A
- Revenue This Year
- AVXL N/A
- REPL N/A
- Revenue Next Year
- AVXL N/A
- REPL N/A
- P/E Ratio
- AVXL N/A
- REPL N/A
- Revenue Growth
- AVXL N/A
- REPL N/A
- 52 Week Low
- AVXL $3.76
- REPL $6.44
- 52 Week High
- AVXL $14.44
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- AVXL 64.24
- REPL 49.26
- Support Level
- AVXL $7.97
- REPL $9.50
- Resistance Level
- AVXL $9.35
- REPL $10.09
- Average True Range (ATR)
- AVXL 0.38
- REPL 0.60
- MACD
- AVXL 0.18
- REPL -0.06
- Stochastic Oscillator
- AVXL 86.10
- REPL 9.76
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.